Medicare Advantage Prompt Pay Act

1) What happened: Representative Arrington (R-TX) introduced HR5454 on September 18, 2025, co-sponsored by 10 members. The bill requires Medicare Advantage organizations to pay 95% of clean claims within 14 days (electronic, contracted) or 30 days (all others). It creates a rebuttable presumption that a claim is received upon provider submission, shifting burden to MA plans. This is early-stage — referred to Ways & Means and Energy & Commerce committees; companion bill S2879 exists in the Senate. No hearings or markups yet. 2) Money trail: The bill authorizes no direct spending or taxes — this is a regulatory mandate, not an appropriation. The economic impact is through increased operational costs for MA plans and improved cash flow for healthcare providers (hospitals, physicians, clinics). Providers benefit from faster payment cycles, improving their working capital. The bill effectively transfers the time value of money from insurers to providers. 3) Winners and losers: Losers are MA plan sponsors — $UNH (UnitedHealthcare), $HUM (Humana, ~90% MA concentration), $ELV (Elevance/Anthem), $MOH (Molina), $CVS (Aetna). Winners are healthcare providers who get paid faster — hospital systems like $HCA, $THC, $UHS, physician groups, and independent labs. The executive order on psychedelic therapies (Apr 18, 2026) is unrelated to MA payment timelines. 4) Real market data: Despite the bearish legislative signal, MA stocks have rallied sharply in the last 7 days: $UNH +3.75% to $366.77, $HUM +5.67% to $229.72, $ELV +10.52% to $362.74, $MOH +21.22% to $185.46, $CVS +5.95% to $80.98. The 30-day trends are even more dramatic: UNH +41.6%, HUM +35.86%, ELV +26.66%, MOH +38.37%, CVS +15.55%. This rally is likely driven by broader market factors (rate expectations, Q1 earnings, sector rotation) rather than legislative momentum for HR5454. The bill is early-stage with low near-term passage probability. 5) Timeline: HR5454 has not advanced since referral in September 2025. With the 119th Congress at midpoint (April 2026), the bill would need committee hearings, markups, House passage, Senate passage (S2879 companion), and presidential action. Given divided government and no committee action in 7 months, passage probability in 2026 is <20%. If reintroduced in 2027 (120th Congress), impact would be delayed.